Vaccine Development

Pfizer, a notable figure in the pharmaceutical industry, is experiencing a transformative phase after the pandemic-era boom. Once dominating the market with its COVID-19 vaccine, Pfizer’s valuation has significantly contracted, moving from an impressive $333.8 billion peak to about $150 billion. This

Pfizer, once hailed globally for pioneering the first FDA-approved Covid vaccine, is witnessing a dramatic shift in its fortunes. At its peak during the pandemic, the pharmaceutical giant’s market value soared to $333.8 billion. Fast forward to now, its valuation has plummeted